Acceleron (XLRN) option implied volatility flat into Phase III Believe results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Anthropic and Accenture partner on embedded AI safety evaluation
Acceleron Pharma (XLRN) Granted FDA Orphan Drug Designation for ACE-083 in Facioscapulohumeral Muscular Dystrophy
July 12, 2018 7:10 AM EDTAcceleron Pharma Inc. (NASDAQ: XLRN) today announced that the United States Food and Drug Administration (FDA) has granted orphan drug designation for ACE-083, the Companys locally acting Myostatin+ muscle agent, for the treatment of patients with facioscapulohumeral muscular dystrophy (FSHD).
We are pleased to receive orphan drug designation for ACE-083, which has shown the potential to address an area of high unmet medical need, said Robert K. Zeldin, M.D., Chief Medical Officer of Acceleron. We believe that ACE-083 could become an important new treatment for patients with FSHD whose muscle weakness negatively affects their... More
Acceleron Pharma (XLRN) PT Raised to $62 at UBS
July 10, 2018 8:01 AM EDTUBS raised its price target on Acceleron Pharma (NASDAQ: XLRN) to $62.00 (from $57.00) while maintaining a Buy rating.
... MoreAcceleron Pharma (XLRN) PT Raised to $74 at H.C. Wainwright Following Positive BELIEVE Results
July 10, 2018 7:34 AM EDTH.C. Wainwright raised its price target on Acceleron Pharma (NASDAQ: XLRN) to $74.00 (from $69.00) while maintaining a Buy rating following the company's announcement, along with Celgene (NASDAQ: CELG), of positive results from the Phase 3 BELIEVE study of luspatercept in... More
